Original articleThe prevalence of metabolic syndrome in patients with hidradenitis suppurativa
Section snippets
Methods
This study was approved by the Henry Ford Hospital Institutional Review Board. A retrospective chart review of 39,055 total encounters in the dermatology clinic from January 1, 2011, to May 31, 2012, was performed. Charts of patients with the International Classification of Diseases, Ninth Revision diagnostic code associated with hidradenitis suppurativa were included. In all, 366 patients with an appropriate diagnosis of hidradenitis suppurativa were identified and included in this
Results
The data consist of 366 cases and 366 controls matched on age ±5 years, sex, and race. If a patient was missing data on 3 or more of these factors, they were excluded from the analysis. Among all 738 patients, 465 (243 patients with hidradenitis suppurativa and 222 control subjects) had enough data to determine the presence or absence of metabolic syndrome, which was defined as having 3 or more of the following: obesity, hypertriglyceridemia, low HDL, diabetes mellitus, and hypertension. All
Discussion
Associations between other disorders known to be associated with increased inflammation, such as psoriasis and rheumatoid arthritis, and metabolic syndrome have previously been investigated and are well documented.15, 16, 17, 18, 19, 20, 21, 22, 23, 24 The link between psoriasis and metabolic syndrome has been particularly well established.15, 16, 17 This disease association appears to increase in a dose-responsive manner with the prevalence of metabolic syndrome increased in proportion to the
References (31)
- et al.
Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota
J Invest Dermatol
(2013) - et al.
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
J Am Acad Dermatol
(2008) - et al.
Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
J Am Acad Dermatol
(2013) - et al.
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom
J Invest Dermatol
(2012) - et al.
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis
Atherosclerosis
(2008) IL-10 family of cytokines
Cytokine Growth Factor Rev
(2010)IL-20: biological functions mediated through two types of receptor complexes
Cytokine Growth Factor Rev
(2010)- et al.
Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection
Cytokine Growth Factor Rev
(2010) - et al.
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
J Am Acad Dermatol
(2011) - et al.
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions
J Invest Dermatol
(2010)
Obesity and metabolic syndrome as related to cardiovascular disease
Expert Rev Cardiovasc Ther
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
JAMA
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey
JAMA
Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women
Arch Intern Med
Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006
Natl Health Stat Report
Cited by (149)
Cytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa
2023, Journal of Investigative DermatologyA Practical Guide for Primary Care Providers on Timely Diagnosis and Comprehensive Care Strategies for Hidradenitis Suppurativa
2023, American Journal of MedicineComorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations
2022, Journal of the American Academy of Dermatology
The Henry Ford Medical Center Department of Dermatology receives support from and this study was funded by the Livingood Fund and Rodzik Fund, neither of which had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclosure: Dr Hamzavi has served and/or currently serves as an investigator in clinical trial activities for the following companies: Galderma, ViroXis, Abbvie, La Roche–Posay, Dow, Centocor, Amgen, Clinuvel, and Pfizer. Dr Hamzavi also serves as a consultant for COMBE. Mr Gold, Dr Reeder, and Ms Mahan have no conflicts of interest to declare.